Wang, Keliang
Luo, Jie
Yeh, Shuyuan http://orcid.org/0000-0002-5329-2321
You, Bosen
Meng, Jialin http://orcid.org/0000-0002-4622-833X
Chang, Philip
Niu, Yuanjie
Li, Gonghui
Lu, Changxue
Zhu, Yezi
Antonarakis, Emmanuel S.
Luo, Jun
Huang, Chi-Ping
Xu, Wanhai
Chang, Chawnshang
Article History
Received: 30 November 2017
Accepted: 6 March 2020
First Online: 1 June 2020
Competing interests
: JL (Johns Hopkins) has served as a paid consultant/advisor for Sun Pharma, Janssen, Tolero, and Sanofi; has received research funding to his institution from Orion, Mirati, Astellas, Sanofi, Constellation, Calibr, Pandomedx, Trovagene, and Gilead; and is a co-inventor of a technology that has been licensed to Tokai, Qiagen, and A&G. CL is a co-inventor of a technology that has been licensed to Tokai and Qiagen. E.S.A. is a paid consultant/advisor to Janssen, Astellas, Sanofi, Dendreon, Pfizer, Amgen, AstraZeneca, Bristol-Myers Squibb, Clovis, and Merck; he has received research funding to his institution from Janssen, Johnson & Johnson, Sanofi, Dendreon, Genentech, Novartis, Tokai, Bristol Myers-Squibb, AstraZeneca, Clovis, and Merck; and he is the co-inventor of an ARv7 biomarker technology that has been licensed to Qiagen. The remaining authors declare no competing interests.